Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 1:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Arthritis Juvenile Idiopathic Clear all
Completed No phase listed Observational
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 19 Years
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 22, 2019 · Synced May 22, 2026, 1:26 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Still's Disease, Adult-Onset, Systemic Inflammation, Arthritis, Autoinflammatory Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
1 Day to 100 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2050
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced May 22, 2026, 1:26 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 24 Months
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced May 22, 2026, 1:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn Disease, Ulcerative Colitis, Plaque Psoriasis, Pediatric Plaque Psoriasis, Pediatric Crohns Disease, Hidradenitis Suppurativa, Non-infectious Uveitis
Interventions
40 mg MSB11022
Drug
Lead sponsor
Fresenius Kabi SwissBioSim GmbH
Industry
Eligibility
18 Years to 55 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced May 22, 2026, 1:26 AM EDT
No Longer Available No phase listed Expanded access
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tocilizumab
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
11 Years to 12 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 9, 2013 · Synced May 22, 2026, 1:26 AM EDT
Withdrawn Phase 1Phase 2 Interventional
View directory record Official record
Conditions
CTLA4 Haploinsufficency, Chronic Cytopenia
Interventions
abatacept, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2023 · Synced May 22, 2026, 1:26 AM EDT
Withdrawn No phase listed Observational
View directory record Official record
Conditions
Arthritis
Interventions
Ultrasound imaging
Device
Lead sponsor
Stanford University
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2011 · Synced May 22, 2026, 1:26 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Systemic Juvenile Idiopathic Arthritis
Interventions
rilonacept (IL-1 Trap), Placebo
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
4 Years to 20 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
9
States / cities
Los Angeles, California • Wilmington, Delaware • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2013 · Synced May 22, 2026, 1:26 AM EDT
Terminated Not applicable Interventional Results available
View directory record Official record
Conditions
Arthritis, Juvenile Rheumatoid, Still's Disease, Juvenile Onset
Interventions
tocilizumab
Biological
Lead sponsor
Tufts Medical Center
Other
Eligibility
2 Years to 16 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced May 22, 2026, 1:26 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Juvenile Psoriatic Arthritis
Interventions
Deucravacitinib, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
5 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
7
States / cities
Lancaster, California • Chicago, Illinois • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced May 22, 2026, 1:26 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Arthritis, Juvenile
Interventions
Ren-Ex Machine, Dual-Emission X-ray Absorptiometry (DEXA) scan, Biodex dynamometer, Sub-maximal test, Quality of life questionnaires
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
10 Years to 21 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced May 22, 2026, 1:26 AM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis Associated Uveitis
Interventions
Tocilizumab
Drug
Lead sponsor
Eric B. Suhler
Other
Eligibility
2 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 13, 2019 · Synced May 22, 2026, 1:26 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic, Arthritis, Juvenile, Adult Onset Still Disease
Interventions
Emapalumab
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
0 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced May 22, 2026, 1:26 AM EDT
Completed No phase listed Observational Results available
View directory record Official record
Conditions
Polyarticular Juvenile Rheumatoid Arthritis, Arthritis, Juvenile Idiopathic
Interventions
Not listed
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
2 Years to 18 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
52
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced May 22, 2026, 1:26 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions, Systemic Juvenile Idiopathic Arthritis (sJIA), Juvenile Rheumatoid Arthritis (JRA)
Interventions
Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa
Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
2 Months to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced May 22, 2026, 1:26 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Systemic Juvenile Idiopathic Arthritis With Active Flare
Interventions
canakinumab, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 19 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
12
States / cities
Little Rock, Arkansas • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced May 22, 2026, 1:26 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Still´s Disease
Interventions
MAS825
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Cincinnati, Ohio • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced May 22, 2026, 1:26 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
tocilizumab [RoActemra/Actemra], Placebo, Non-steroidal anti-inflammatory drugs (NSAIDs), methotrexate, corticosteroids
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 17 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
13
States / cities
Little Rock, Arkansas • Los Angeles, California • Hartford, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2016 · Synced May 22, 2026, 1:26 AM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
SLEEPSAMRT
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
8 Years to 13 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced May 22, 2026, 1:26 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Active Polyarticular Juvenile Idiopathic Arthritis
Interventions
Abatacept
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
2 Years to 17 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
12
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Hartford, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced May 22, 2026, 1:26 AM EDT
Terminated No phase listed Observational Results available
View directory record Official record
Conditions
Arthritis, Juvenile Rheumatoid
Interventions
Celecoxib, nsNSAIDs
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
27
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Washington D.C., District of Columbia + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced May 22, 2026, 1:26 AM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Systemic Juvenile Idiopathic Arthritis
Interventions
Canakinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 19 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced May 22, 2026, 1:26 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Anterior Uveitis, Arthritis, Juvenile Idiopathic, Iritis, Immunosuppression
Interventions
Daclizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
6 Years to 18 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced May 22, 2026, 1:26 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 18 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
9
States / cities
Little Rock, Arkansas • Chicago, Illinois • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced May 22, 2026, 1:26 AM EDT